How to Cite
Abstract
There was conducted an assessment of the effectiveness of a combination of systemic and regional modes of chemotherapy versus systemic chemoinfusion in treatment of 70 patients with unresectable metastases of colorectal cancer in the liver after extrahepatic progression of a disease. The use of combined therapy statistically significantly increased overall survival more than doubled as compared to a group of systemic chemotherapy (median 10 vs. 4.5 months, p = 0,002) as well as the time before intrahepatic progression (median 5.9 vs. 3.5 months, p = 0.01). In addition, there was a trend toward a greater frequency of objective responses in the combination therapy group 18% in comparison with 9.7% in the systemic chemotherapy group (p = 0.49) but the difference was not statistically significant and it needed further study on more clinical material.References
Гранов Д.А., Таразов П.Г. Рентгенэндоваскулярные вмешательства в лечении злокачественных опухолей печени. — Спб.: Фолиант, 2002. — 288 с.
Матвеев Н.Л., Борсуков А.В., Сергеева О.Н. Электрохимический лизис в эксперименте и в сравнительной характеристике с радиочастотной аблацией при лечении злокачественных новообразований в печени // Эндоскоп. Хир. — 2009. — № 2. — С. 19-27.
Таразов П.Г. Роль методов интервенционной радиологии в лечении больных с метастазами колоректального рака в печень // Практ. онкол. — 2005. — Т. 6. — № 2. — С. 119-126.
Трякин А.А. Лекарственное лечение метастатического колоректального рака // Практ. онкол. — 2005. — Т. 6. — № 2 — С. 112-118.
Abdel-Misih S.R.Z., Schmidt C.R., Bloomston P.M. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases // World J. Surg. Oncol. — 2009. — Vol. 7. — P. 69-72.
Abitabil P., Hartl U., Lange J. et al. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis // EJSO. — 2007. — Vol. 33. — P. 67-71.
Ackerman N.B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth // Surg. — 1974. — Vol. 75. — P. 589-596.
Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-ar-tery floxuridine infusion for colorectal liver metastases. // Lancet. 1994 Nov 5; 344 (8932): 1255-60.
Blanke C. D. Rational treatment planning for isolated, potentially curable liver metastases // Comm. Oncol. — 2007. — Vol. 4. — № 7. (suppl.3). — P. 11-16.
Byam J., Reuter N.P., Woodal C.H., et al. Should hepatic metastatic colorectal cancer patients with extrahepatic disease undergo liver resection/ablation? // Ann. Surg. Oncol. — 2009. — Vol. 16. — P. 3064-3069.
Carpizo D. R., D’Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease // Ann. Surg. Oncol. — 2009. — Vol. 16. — P. 2411-2421.
Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M., Steinberg S.M. A prospective randomized trial of regional versus systemic continuous 5-fluorode-oxyuridine chemotherapy in the treatment of colorectal liver metastases // Ann. Surg. 1987 Dec; 206 (6): 685-93.
Ducreux M., Ychou M., Laplanche A. et al. Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer // J. Clin. Oncol. — 2005. — Vol. 23. — P. 4881-4887.
Elias D., Liberale G., Vernerey D., et al. Hepatic and ex-trahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect // Ann. Surg. Oncol. — 2005. — Vol. 12. — P. 900-909.
Goldberg R.M. Advances in the treatment of metastatic colorectal cancer // Oncologist. — 2005. — Vol. 10 (sup-pl. 3). — P. 40-48.
Goldberg R.M. Therapy for metastatic colorectal cancer // The Oncologist. — 2006. — Vol. 11. — P. 981-987.
Goldberg R.M., Meropol N.,J., Tabernero J. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer // Gastroint. Cancer Res. — 2009. — Vol. 3. — № 5 (suppl. 2). — P. 23-27.
Hohn D.C., Stagg R.J., Friedman M.A., Hannigan J.F. Jr, Rayner A., Ignoffo R.J., Acord P., Lewis B.J. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. // J. Clin. Oncol. 1989 Nov; 7 (11): 1646-54.
Kemeny N.E., Niedzwieck D., Hollis D.R. et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481) // J. Clin. Oncol. — 2006. — Vol. 24. — № 9. — P. 1-9.
Kerr D.J., McArdle C.S., Ledermann J., Taylor I., Sherlock D.J., Schlag P.M., Buckels J., Mayer D., Cain D., Stephens R.J. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. // Lancet. 2003 Feb 1; 361 (9355): 368-73.
Loong H.H., Ma B.B., Chan A.T.C. Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer // J. Oncol. — 2009. — Vol. 9. — P. 1-6.
Maiello E., Gebbia V., Giuliani F. et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell’Italia Meridionale (GOIM) // Ann. Oncol. — 2005. — Vol. 16 (suppl. 4). — P. 56-60.
Martin D.S. Introduction to 5-fluorouracil modulation. // Cancer Invest. 1990; 8(2): 257-8.
Neumann U.P., Seehofer D., Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma // Deut. Ärztebl. Int. — 2010. — Vol. 10. — P. 335-342.
Park J.O., Lee S.I., Song S.Y. et al. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria // Jpn. J. Clin. Oncol. — 2003. — Vol. 33. — P. 533-537.
Paschos K.A., Bird N., Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis // Hippokratia. — 2008. — Vol. 12. — P. 132-138.
Power D. G., Healey-Bird B. R., Kemeny N.E. Regional chemotherapy for liver-limited metastatic colorectal cancer // Clin. Colorectal Cancer. — 2008. — Vol. 7. — P. 247-259.
Reichman B.S., Kemeny N.,E., Yeh S.D. A complication of prolonged infusional chemotherapy masquerading as a bone metastasis in a patient with colorectal carcinoma // Cancer. 1987 Mar 15; 59 (6): 1098-100.
Rougier P., Laplanche A., Huguier M., Hay J.M., Ollivier J.M., Escat J., Salmon R., Julien M., Roullet Audy J.C., Gallot D., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial // J. Clin. Oncol. 1992 Jul; 10 (7): 1112-8.
Sheth R.K., M.D., Clary B.M., M.D. Management of hepatic metastases from colorectal cancer // Clin.Colon Rectal Surg. — 2005. — Vol. 18. — P. 215-223.
Stratmann S.L., M.D. Hepatic artery chemotherapy in the management of colorectal metastases // Bayl. Univ. Med. Cent. Proceedigs. — 2002. — Vol. 15. — P. 376-379.
Therasse P., Arbuck S.G., Eisenhaueret E.A. al. New guidelines to evaluate the response to treatment in solid tumors // J. Nat. Cancer Inst. — 2000. — Vol. 92. — P. 205-216.
Verweija J., Therasseb T., Eisenhauerc E., on behalf of the RECIST working group. Cancer clinical trial outcomes: Any progress in tumour-size assessment? // Europ. J. Cancer. — 2009. — Vol. 45. — P. 225-227.
Winawer S., Classen M., Lambert R. et al. Скрининг колоректального рака // WGO Practice Guidelines. — 2008. — P. 1-17.
Yang Y.Y.L., Fleshman J.W., Strasberg S.M. Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases // J. Gastrointest. Surg. — 2007. — Vol. 11. — P. 929-944.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...